menu
    • menu
    [{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Michigan Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||RAGE","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Michigan Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Cantex Pharmaceuticals \/ Michigan Medicine"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Michigan Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||RAGE","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Michigan Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Cantex Pharmaceuticals \/ Michigan Medicine"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Cantex Pharmaceuticals \/ Medpace, Inc"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Lenox Hill Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||RAGE","graph1":"Oncology","graph2":"Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Lenox Hill Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Cantex Pharmaceuticals \/ Lenox Hill Hospital"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||RAGE","graph1":"Oncology","graph2":"Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||RAGE","graph1":"Oncology","graph2":"Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||RAGE","graph1":"Oncology","graph2":"Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||RAGE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"||RAGE","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||RAGE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||RAGE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"vTv Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"||RAGE","graph1":"Oncology","graph2":"Phase I","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cantex Pharmaceuticals \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Cantex Pharmaceuticals \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Miami Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||RAGE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Miami Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Miami Cancer Institute"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"||RAGE","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Cantex Pharmaceuticals \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sulfiram","moa":"||Aldehyde dehydrogenase","graph1":"Oncology","graph2":"Phase I","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cantex Pharmaceuticals \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Cantex Pharmaceuticals \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cantex Pharmaceuticals \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Cantex Pharmaceuticals \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Harvard University","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"||RAGE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cantex Pharmaceuticals \/ Harvard University","highestDevelopmentStatusID":"6","companyTruncated":"Cantex Pharmaceuticals \/ Harvard University"}]

    Find Clinical Drug Pipeline Developments & Deals by Cantex Pharmaceuticals

    Menu

    Cantex Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cantex Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Cantex Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azeliragon,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Washington University School of Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblast...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 18, 2025

                            Lead Product(s) : Azeliragon,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Washington University School of Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cantex Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Cantex Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azeliragon,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cantex Receives FDA ODD for Azeliragon in Brain Metastasis from Breast Cancer

                            Details : TTP488 (azeliragon) is an oral capsule, inhibiting interactions of the receptor for advanced glycation end products with ligands, including HMGB1 and S100 proteins in the tumor microenvironment.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 09, 2024

                            Lead Product(s) : Azeliragon,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cantex Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Cantex Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azeliragon,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cantex Pharmaceuticals Gets FDA Orphan Drug Status for Azeliragon in Pancreatic Cancer

                            Details : TTP488 (azeliragon) is an oral capsule, inhibiting interactions of the receptor for advanced glycation end products with ligands, including HMGB1 and S100 proteins in the tumor microenvironment.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 20, 2024

                            Lead Product(s) : Azeliragon,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cantex Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Cantex Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azeliragon,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Michigan Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled, Multicente...

                            Details : TTP488 (azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). It is being investigated for the treatment of hospitalized patients for COVID-19 infection.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 27, 2023

                            Lead Product(s) : Azeliragon,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Michigan Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cantex Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Cantex Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azeliragon,Dexamethasone

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refract...

                            Details : TTP488 (azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). It is being investigated for the treatment of refractory to first-line treatment of metastatic pancreatic cancer.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 26, 2023

                            Lead Product(s) : Azeliragon,Dexamethasone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cantex Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Cantex Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azeliragon,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Lenox Hill Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cantex Pharmaceuticals and Lenox Hill Hospital Announce Initiation of a Phase 2 Study of RAGE Inhibitor Azelir...

                            Details : TTP488 (azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). It is being investigated for the treatment of patients newly diagnosed unmethylated glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 18, 2023

                            Lead Product(s) : Azeliragon,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Lenox Hill Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cantex Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Cantex Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azeliragon,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cantex Pharmaceuticals Receives FDA Orphan Drug Designation for Azeliragon for The Treatment of Glioblastoma

                            Details : TTP488 (Azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). A broad range of evidence suggests that RAGE ligand interactions play a critical role in cancer and in inflammatory diseases.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 01, 2023

                            Lead Product(s) : Azeliragon,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cantex Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Cantex Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azeliragon,Dexamethasone

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cantex Pharmaceuticals Announces Initiation of an Investigator-Initiated Phase 2 Clinical Trial Investigating ...

                            Details : Azeliragon is an orally administered capsule, taken once daily, that inhibits interactions of RAGE with certain ligands, including HMGB1 and S100 proteins in the tumor microenvironment.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 28, 2023

                            Lead Product(s) : Azeliragon,Dexamethasone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cantex Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Cantex Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azeliragon,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Medpace, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Azeliragon in MGMT Unmethylated Glioblastoma

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 14, 2023

                            Lead Product(s) : Azeliragon,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Medpace, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Cantex Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Cantex Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azeliragon,Cyclophosphamide,Doxorubicin Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Recipient : Georgetown University

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from George...

                            Details : Under the agreement, Cantex gets exclusive worldwide license for intellectual property related to the potential use of TTP488 (azeliragon), a small molecule RAGE inhibitor, to treat, prevent or alleviate cancer treatment-related cognitive decline.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 16, 2023

                            Lead Product(s) : Azeliragon,Cyclophosphamide,Doxorubicin Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Georgetown University

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth